Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects With PAH Deficiency

NCT03952156 is registered in ClinicalTrials.gov with Homology Medicines, Inc as lead sponsor.

NCT NCT03952156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03952156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-Label, Randomized, Concurrently-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of HMI-102 in Adult PKU Subjects With PAH Deficiency
Lead sponsor
Homology Medicines, Inc
Phase
Phase 1/2
Overall status
Terminated
Start date
June 10, 2019
Completion date
August 1, 2023
Enrollment
10 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

pah deficiency, phenylketonurias